Delivery Order SPE2DB20D1109-SPE2DB25FP76Z
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $3,608.26 on December 11, 2025, for 100-count tablets of Envarsus XR 4 mg, with completion targeted for January 5, 2026. This competitively awarded, firm fixed-price delivery order leverages AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The delivery will be performed at AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 17, 2025, for the supply of Envarsus XR 1 mg tablets (100 count) with a ceiling value of $1,288.86. This firm fixed-price delivery order, which must be completed by November 7, 2025, represents a non-set-aside, competitively awarded contract. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Envarsus XR 1 mg tablets in quantities of 100 units, with a contract ceiling value of $1,718.48. This firm fixed-price delivery order, with an ultimate completion date of October 1, 2025, represents a non-set-aside competitive award to support federal medical procurement requirements. The award is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of Envarsus XR 4 mg tablets (100-count packages) with a contract ceiling value of $1,711.95. This firm fixed-price delivery order, which has an ultimate completion date of October 16, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was made through open competition with no set-aside...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 10, 2025, for the supply of Envarsus XR 4 mg tablets (100-count units) with a ceiling value of $3,608.26. This is a firm fixed-price delivery order with no set-aside designation, placing performance in Conshohocken, Pennsylvania, and scheduled for completion by December 3, 2025. The award represents a competitively awarded transaction under AmerisourceBergen's existing Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 13, 2025, for the supply of Envarsus XR 4 mg tablets in quantities of 100 units. This is a firm fixed-price delivery order valued at $5,412.39, with performance to be completed by December 5, 2025, at the contractor's location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation. This delivery order represents a child contract issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Envarsus XR 1 mg tablets in a quantity of 100 units. This competitively awarded, non-set-aside contract carries a ceiling value of $1,718.48 with firm fixed pricing and is scheduled for completion by September 11, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Envarsus XR 4 mg tablets (100 count) with a contract value of $4,283.14 and an ultimate completion date of September 9, 2025. This is a firm fixed price delivery order issued under a non-set-aside competitive procurement. The award represents a child contract under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Envarsus XR 1 mg tablets (100-count units) with a contract ceiling value of $1,288.86. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The award utilized no set-aside designation and was...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 12, 2025, for the supply of Envarsus XR 4 mg tablets (100-count units) valued at $3,608.26. This competitively awarded, non-set-aside contract utilizes firm fixed-price pricing and is scheduled for completion by December 4, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters and primary...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB25FP76ZDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Envarsus XR 4 mg tablets (100-count units) under a firm fixed-price contract with a ceiling value of $4,712.76. The contract is scheduled for completion by October 7, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania location. This delivery order represents a non-set-aside, competitively awarded procurement and is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical supplier to the Defense Logistics Agency's medical supply chain, providing a comprehensive range of pharmaceutical products and medical supplies to support military and veteran healthcare systems. The company's prime IDV vehicle enables the procurement of specialty medications, brand-name and generic drugs, vaccines, and related medical commodities across multiple therapeutic domains, supporting customers including the Defense Health Agency and U.S. Coast Guard. This specific delivery order for Envarsus XR—an immunosuppressant medication—exemplifies the company's role in supplying essential pharmaceutical products through the DLA's streamlined procurement process.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.7k | 9/16/25 |